Alefacept in Patients With Relapsed/Refractory Aplastic Anemia
| Status: | Terminated |
|---|---|
| Conditions: | Anemia |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/28/2018 |
| Start Date: | May 2011 |
| End Date: | April 16, 2013 |
A Phase 1/2 Study of Alefacept, a CD2 Receptor Antagonist in Patients With Relapsed/Refractory Aplastic Anemia
Aplastic Anemia (AA) is an autoimmune hematologic stem cell disease mediated by activated
T-lymphocytes that leads to pancytopenia. The disease related morbidity and mortality if left
untreated can approach 90%. For over 30 years, anti-thymocyte globulin (ATG) in combination
with cyclosporine (CsA) remains the standard therapy. However, the treatment response with
ATG is at best between 50-60% with a sizeable number of partial responses. Treatment with ATG
is also associated with significant toxicity and high relapse rate that can be as high as
45%. Since the prognosis in refractory and relapsed AA remains poor, there is a need for less
toxic novel immunosuppressive agents that can improve response rates and remission duration
in refractory and relapsed AA.
Alefacept is a human recombinant dimeric fusion protein composed of the terminal portion of
leukocyte functioning antigen-3 (LFA3/CD58) and the Fc portion of human IgG1. It prevents
co-stimulatory signals between antigen presenting cells and memory T cells by competitive
inhibition of CD2 in T cells, induces selective apoptosis of CD4+ and CD8+ memory effector T
cells by interaction between the Fc portion of IgG1 and the FcyIII in NK cells, and possibly
direct ligation of CD2 molecules on T cells that subsequently result in the alteration in T
cell agonist signaling. It has been used successfully in the treatment of other T cell
mediated disorders particularly psoriasis and steroid refractory graft versus host disease
(GVHD) with minimal side effects. In a case of liver transplant associated AA (similar to
transfusion associated AA) which is fatal in most patients, Alefacept induced remission after
patient did not respond to ATG and other immunosuppressants. The investigators hypothesize
that the LFA3-CD2 co-stimulatory pathway play an important role in the immune pathogenesis of
AA and treatment with Alefacept can help treat refractory/relapsed cases of AA.
T-lymphocytes that leads to pancytopenia. The disease related morbidity and mortality if left
untreated can approach 90%. For over 30 years, anti-thymocyte globulin (ATG) in combination
with cyclosporine (CsA) remains the standard therapy. However, the treatment response with
ATG is at best between 50-60% with a sizeable number of partial responses. Treatment with ATG
is also associated with significant toxicity and high relapse rate that can be as high as
45%. Since the prognosis in refractory and relapsed AA remains poor, there is a need for less
toxic novel immunosuppressive agents that can improve response rates and remission duration
in refractory and relapsed AA.
Alefacept is a human recombinant dimeric fusion protein composed of the terminal portion of
leukocyte functioning antigen-3 (LFA3/CD58) and the Fc portion of human IgG1. It prevents
co-stimulatory signals between antigen presenting cells and memory T cells by competitive
inhibition of CD2 in T cells, induces selective apoptosis of CD4+ and CD8+ memory effector T
cells by interaction between the Fc portion of IgG1 and the FcyIII in NK cells, and possibly
direct ligation of CD2 molecules on T cells that subsequently result in the alteration in T
cell agonist signaling. It has been used successfully in the treatment of other T cell
mediated disorders particularly psoriasis and steroid refractory graft versus host disease
(GVHD) with minimal side effects. In a case of liver transplant associated AA (similar to
transfusion associated AA) which is fatal in most patients, Alefacept induced remission after
patient did not respond to ATG and other immunosuppressants. The investigators hypothesize
that the LFA3-CD2 co-stimulatory pathway play an important role in the immune pathogenesis of
AA and treatment with Alefacept can help treat refractory/relapsed cases of AA.
OBJECTIVES:
1. Primary Objective
- To define the safety, tolerability, dose-limiting toxicities (DLT), of alefacept in
relapsed/ refractory aplastic anemia (AA).
- To evaluate the efficacy of alefacept in refractory/ relapsed AA by determining
overall response rates (ORR) which includes complete remission [CR] and partial
remission (PR) rates.
2. Secondary Objective
- To evaluate for predictive markers for response to Alefacept with relapsed/
refractory AA and evaluate its effect on the PNH clone. The effects of alefacept in
major populations of lymphocytes will be evaluated. The absolute numbers of various
T cell populations including CD3+ T cell, CD3+/CD4+ T cell, CD3+/CD8+, CD57+
natural killer cell count and CD4/CD8 ratio will be measured as part of an
immunodeficiency panel by flow cytometry. The functional properties of T cells will
be evaluated by measuring markers of T cell activation and cytokine production. The
saturation of CD2 receptors with alefacept will be determined. Occupied CD2 will
not be detectable by competing antibody in-vitro. The expression of CD2 within
lymphocytes will be measured prior to the initiation of therapy and every 2 weeks
prior to and 30 minutes after the administration of alefacept. The presence of a
Paroxysmal Nocturnal Hemoglobinuria (PNH) clone in patients with AA has been shown
to correlate with increased response to immunosuppression25.
OUTLINE: This is an open-label, single center study. Patients will receive intravenous
Alefacept once weekly for a total of 12 weeks in the absence of disease progression or
unacceptable toxicity. After completion of the 12 week treatment, patients will go through a
12 week observation period. After completion of the study, patients will be followed
periodically. The dose defined in the Phase 1 study will be used for the subsequent Phase 2
study. Four bone marrow biopsies will be taken at screening, week 13, week 24, and the end of
study.
1. Primary Objective
- To define the safety, tolerability, dose-limiting toxicities (DLT), of alefacept in
relapsed/ refractory aplastic anemia (AA).
- To evaluate the efficacy of alefacept in refractory/ relapsed AA by determining
overall response rates (ORR) which includes complete remission [CR] and partial
remission (PR) rates.
2. Secondary Objective
- To evaluate for predictive markers for response to Alefacept with relapsed/
refractory AA and evaluate its effect on the PNH clone. The effects of alefacept in
major populations of lymphocytes will be evaluated. The absolute numbers of various
T cell populations including CD3+ T cell, CD3+/CD4+ T cell, CD3+/CD8+, CD57+
natural killer cell count and CD4/CD8 ratio will be measured as part of an
immunodeficiency panel by flow cytometry. The functional properties of T cells will
be evaluated by measuring markers of T cell activation and cytokine production. The
saturation of CD2 receptors with alefacept will be determined. Occupied CD2 will
not be detectable by competing antibody in-vitro. The expression of CD2 within
lymphocytes will be measured prior to the initiation of therapy and every 2 weeks
prior to and 30 minutes after the administration of alefacept. The presence of a
Paroxysmal Nocturnal Hemoglobinuria (PNH) clone in patients with AA has been shown
to correlate with increased response to immunosuppression25.
OUTLINE: This is an open-label, single center study. Patients will receive intravenous
Alefacept once weekly for a total of 12 weeks in the absence of disease progression or
unacceptable toxicity. After completion of the 12 week treatment, patients will go through a
12 week observation period. After completion of the study, patients will be followed
periodically. The dose defined in the Phase 1 study will be used for the subsequent Phase 2
study. Four bone marrow biopsies will be taken at screening, week 13, week 24, and the end of
study.
Inclusion Criteria:
1. Fulfilled criteria for diagnosis of either moderate (mAA) or severe aplastic anemia
(sAA) at the time of initial diagnosis defined per protocol.
2. Patient with a history sAA must have had an incomplete response at least 3 months
following treatment with ATG/CsA, or they must have relapsed following an initial
response to treatment.
3. Patient must not be receiving any cyclosporine or any other T cell immunosuppressive
agents within 4 weeks of study entry.
4. Patients must have organ function as defined below:
- total bilirubin within normal institutional limits (NV: 0.0-1.5 mg/dL)
- AST(SGOT)/ALT(SGPT) <2.5 X institutional upper limit of normal AST (NV: 7-40
U/L); ALT (NV: Male 5-50 U/L; Female 0-45 U/L)
- creatinine within normal institutional limits (NV: Age 18 0.4-1.3 mg/dL; 19-99
years old 0.7-1.4 mg/dL) OR
- creatinine clearance >60 mL/min/1.73 m2 for patients with creatinine levels above
institutional normal.
5. Peripheral blood counts at the time of enrollment must include at least one of the
following: Hgb <9 g/dL or red blood cell (RBC) transfusion dependence, ANC <1000/µl,
or platelet count of <60,000/µL.
6. Women of child-bearing potential and men must agree to use adequate contraception
defined per protocol.
7. Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
1. Patients may not be receiving any other investigational agents (other than
hematopoietic growth factors) within 4 weeks of study entry.
2. History of allergic reactions attributed to compounds of similar chemical or biologic
composition to Alefacept.
3. Current diagnosis of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS),
Fanconi's anemia, Dyskeratosis Congenita (DC) or other hereditary forms of AA.
4. Psychiatric, addictive or any other disorder that compromises ability to give a truly
informed consent.
5. Age <18 years.
6. ECOG performance status >2 (Karnofsky <60%, see Appendix A).
7. Malignancy other than non-melanoma skin cancer within the last 2 years.
8. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection (defined as uncontrolled infection requiring IV antibiotics, invasive fungal
infection and progressive CMV viremia), symptomatic congestive heart failure (NYH
class III and IV), unstable angina pectoris, or cardiac arrhythmia.
9. Pregnant or breastfeeding women.
10. HIV-positive patients on combination antiretroviral therapy.
11. Patients who have previously received systemic chemotherapy and/ or radiation therapy.
12. Patients who previously underwent allogeneic hematopoietic stem cell transplant.
We found this trial at
1
site
Click here to add this to my saved trials
